Alzheimer's drug Leqembi receives go ahead from the FDA to be used in patients
Eisai achieves FDA approval for it's Alzheimer's disease drug Leqembi, after rigorous testing in clinical trials show it reduces the size of characteristic plaques in the brains of patients.
After many stages of testing and intense review, the Eisai R&D Management drug for Alzheimer’s disease, Leqembi, has been approved by the US FDA.
Leqembi is the brand name for the drug lecanemab-irmb, the second of such drugs to be approved for the treatment of Alzheimer’s by targeting the pathology of the disease, aiming to reduce the amyloid plaques in the brain that are inherent to the disease.
“Alzheimer’s disease immeasurably incapacitates the lives of those who suffer from it and has devastating effects on their loved ones,” stated Billy Dunn, Director of the Office of Neuroscience in the FDA’s Centre for Drug Evaluation and Research. “This treatment option is the latest therapy to target and affect the underlying disease process of Alzheimer’s, instead of only treating the symptoms of the disease.”
Leqembi was tested in a Phase III, double-blind, placebo-controlled, parallel-group, dose-finding study, which included 856 patients with Alzheimer’s disease, who had confirmed presence of amyloid beta plaques, identified using positron emission tomography (PET), and mild cognitive impairment.
The test participants were given 10 mg/kg of lecanemab every two weeks. When compared to the control group at 79 weeks post start of treatment, the test subjects showed a statistically significant decrease in amyloid-beta plaques in the brain; the control group demonstrated no reduction in plaque build-up.
These remarkable test results led to the accelerated approval of Leqembi, based on the reduction in plaques after PET in areas of the brain most likely to be affected.
On prescription, Leqembi does come with a warning against amyloid-related imaging abnormalities (ARIA), which can develop with this class of antibodies. ARIA do not regularly give rise to symptoms, but serious and life-threatening adverse events have been known to occur, which did stir up concerns in the testing phase, but were mollified after further investigation. ARIA is commonly characterized by temporary swelling in the some areas of the brain and may also introduce small bleeds on the brain giving rise to symptoms such as headaches, confusion, dizziness, and seizure. The most common side-affects of Leqembi were headaches and ARIA.
The approval of the drug only covers the specific use as was tested in the clinical trial, i.e patients with mild cognitive impairment or mild dementia stage of disease. There is currently no data to show whether there is any difference in safety or efficacy if the drug is used in patients at earlier or later stages of disease progression. This is something that will have to be elucidated in further clinical trials.
Approval granted under Fast Track, Priority Review and Breakthrough Therapy designations is a big achievement in the ongoing battle to find effective treatments for Alzheimer’s disease and is a promising step for testing drugs in this class.
For more big drug approvals to watch out for in 2023, see our recent article on the major drug approvals of recent times here.
Related News
-
News On Track at Pharmapack 2024 - The Track Sponsor interview: BD Pharmaceuticals
January 2024 brings both a new year and Europe’s leading packaging and drug delivery event. Bringing the world’s experts in pharmaceutical packaging together in Paris, France, Pharmapack 2024 brings exciting opportunities to learn and colla... -
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News Roche breaks into the obesity drug market with the acquisition of Carmot Therapeutics
In a bid to diversify their therapeutic offerings, Roche takes over Carmot Therapeutics in $2.7 billion deal, with one obesity drug spearheading the venture into the field as they prep for a Phase II in-human trial. -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News Women in Pharma: Delivering solutions for gender diversity
In our new monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona Speaker Interview – What the US FDA’s Quality Management Maturity Means for the Pharma Industry
At CPHI Barcelona (24–26 October, 2023), we spoke to Sireesha Yadlapalli, CEO of Pharmatech Associates, who gave a presentation on the implications of the US FDA’s Quality Management Maturity (QMM) Initiative, and spoke on the panel of the ... -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News Wegovy and weight-loss drugs driving demand for manufacturers that can fill syringes
Injectable weight-loss treatments are prompting contract manufacturers to invest and include fill-finish services into their service portfolios, in a bid to attract pharmaceutical giants developing drugs similar to Novo Nordisk's Wegovy.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance